Aviceda Therapeutics Appoints Industry Veteran Dr. Jeffrey Nau as Chief Executive Officer to Lead Next Phase of Growth and Innovation ...

Aquestive's Anaphylm, which is set for an imminent FDA filing, has blockbuster potential. See why I think AQST stock is a buy ...

ARS Pharma has claimed FDA approval for its epinephrine nasal spray neffy, becoming the first ... such as Kaléo's AUVI-Q and Viatris' EpiPen – which dominates the market for emergency ...

ARS Pharmaceuticals, Inc.'s stock soared 25% on strong earnings. Learn about neffy's market potential, risks, and future ...

The nasal spray, dubbed neffy, has been filed for use in adults and children weighing 30 mg or more as an alternative to epinephrine injections such as Kaléo’s AUVI-Q and Viatris’ EpiPen ...

Shares of ARS Pharmaceuticals bounded higher Thursday after the company reported an unexpected fourth-quarter metrics.

Milestone Pharmaceuticals said on Friday the U.S. health regulator had declined to approve its nasal spray to treat a type of ...

The Food and Drug Administration (FDA) has issued a Complete Response Letter to Milestone Pharmaceuticals regarding the New Drug Application (NDA) for ...

The Food and Drug Administration has turned away a proposed nasal spray from Milestone Pharmaceuticals to treat a type of irregular heartbeat over concerns about how the drug is manufactured.

A recent study led by Mass General Brigham researchers found that a nasal spray developed to target inflammation in the brain could be used to treat chronic symptoms of traumatic brain injury.

March 6, 2025 – The FDA has approved a new nose spray that can quickly treat severe ... Common side effects include nasal discomfort or tingling, nosebleeds, sneezing, runny or dry nose or ...